

[ABSTRACT]

An object of the present invention is to provide a medicine that is a non-ergot DA, reduces a risk of somnolence as a side effect, and exhibits an excellent therapeutic effect against neurodegenerative diseases such as PD.

The present invention relates to a pharmaceutical composition for treating a neurodegenerative disease such as Parkinson's disease including: 1-{{(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinoline-6-yl}carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof, wherein the compound is orally administered in an amount of 0.25 mg to 2 mg in terms of a free form equivalent value as a daily dose.